September 14, 2022
Research Report
Independent analysis
Report ID: 25209

noble

Ayala Pharmaceuticals Inc. (AYLA) - Phase 2/3 RINGSIDE Data Presented, Dose Selected For Next Stage


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
0 min read
Get a Report
Refer to the full report for the price target, fundamental analysis, and rating.

The Company in this report is a participant in the Company Sponsored Research Program (“CSRP”); Noble receives compensation from the Company for such participation. No part of the CSRP compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed by the analyst in this research report.

The Company has attended Noble investor conference(s) in the last 12 months.

Noble intends to seek compensation for investment banking services and non-investment banking services (securities and non-securities related) within the next 3 months.


Ayala Pharmaceuticals Inc.
Ayala Pharmaceuticals Inc.
Healthcare
Biotechnology
Ticker
AYLA
Current Price
$0.9939 5.05%
Market Cap
$14.7M
Price Target
Refer to Report
Volume
71.0K
52wk Range
$0.7 - $14.5
Related Research Reports
9/20/2022

Lowering AYLA To Market Perform
Lowering AYLA To Market Perform (AYLA)
9/14/2022

Phase 2/3 RINGSIDE Data Presented, Dose Selected For Next Stage
Phase 2/3 RINGSIDE Data Presented, Dose Selected For Next Stage (AYLA)
8/17/2022

RINGSIDE Data Presentation Announced With 2Q Results
RINGSIDE Data Presentation Announced With 2Q Results (AYLA)
7/27/2022

Stock Rises As Data Milestone Approaches and Public Offering Cancelled
Stock Rises As Data Milestone Approaches and Public Offering Cancelled (AYLA)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2022 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.